This site is intended for healthcare professionals

Cimzia is the first and only biologic approved in Europe with the option for a reduced maintenance dose for patients across the full axial spondyloarthritis spectrum- UCB.

Read time: 1 mins
Last updated:28th Jun 2021
Published:8th Aug 2020
Condition: Axial Spondyloarthritis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest